Tvardi Therapeutics (TVRD) had a good Tuesday. The stock jumped nearly 50% after the company reported Phase 1 results for TTI-109, its next-generation STAT3 inhibitor. The investigational therapy showed rapid conversion to its active form, dose-proportional pharmacokinetics, evidence of target engagement, and — importantly — improved tolerability compared with its predecessor, TTI-101.

TTI-109 is a phosphate prodrug of TTI-101, designed to improve drug delivery and tolerability while maintaining the same mechanism of action. The Phase 1 study showed that TTI-109 converted to TTI-101 within two hours and achieved nearly identical plasma exposure at molar-equivalent doses. That validates the prodrug approach — the drug does what it's supposed to do.

After 21 days of repeat dosing, TTI-101 concentrations remained above the STAT3 IC₅₀, with pharmacokinetics staying stable and dose proportional. In an exploratory pharmacodynamic analysis, the study showed reductions of up to 60% in STAT3-driven immune cell populations. That's a strong signal that the drug is hitting its target.

The tolerability data were particularly encouraging. Diarrhea events associated with TTI-109 were comparable to placebo in duration and resolved without treatment interruption. Compared with near-equivalent doses of TTI-101, diarrhea episodes with TTI-109 were substantially shorter — averaging 0.46 days versus 3.35 days. That's a meaningful improvement for patients.

Tvardi plans to pursue dermatologic and gastrointestinal diseases where STAT3 serves as a central signaling node linking cytokines, growth factors, and immune pathways. The company believes TTI-109's mechanism may address both inflammatory and proliferative processes with a single oral therapy. Prior preclinical models and clinical studies of its STAT3 inhibitors demonstrated activity across inflammation, fibrosis, and immune regulation, and the TTI-109 healthy volunteer study further extended those findings by reducing STAT3-driven immune cell populations.

Of course, there's still a long road ahead. Tvardi noted that future clinical development will depend on clearance of an Investigational New Drug application and the availability of additional funding. But for now, the data are promising, and the market is taking notice. Shares were up 49.75% at $3.010 at the time of publication on Tuesday.